Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis

David Gillis*, Nir Yetiv, Michael Gdalevich, Daniel Mimouni, Isaac Ashkenazi, Ofer Shpilberg, Arieh Eldad, Joshua Shemer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)3005-3010
Number of pages6
JournalVaccine
Volume18
Issue number26
DOIs
StatePublished - 1 Jul 2000

Keywords

  • Hepatitis A
  • Immune Serum Globulin
  • Inactivated HAV vaccine

Fingerprint

Dive into the research topics of 'Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis'. Together they form a unique fingerprint.

Cite this